NEW YORK (GenomeWeb News) — Nanogen yesterday reported that third-quarter revenues bolted upwards 134 percent on dramatic increases in product sales, but the company posted a 34-percent increase in net loss.
Total receipts for the quarter ended Sept. 30 increased to $7.5 million from $3.2 million year over year.
R&D spending in the quarter doubled to $6.2 million, Nanogen said.
Nanogen said net losses for the period swelled to $11.8 million from $8.8 million year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.